title: Intermittent androgen deprivation therapy with antagonist: really new information?
authors.affiliation: Urology Department, University Hospital, Hôpital Nord, St Etienne, France. Electronic address: Nicolas.mottet@chu-st-etienne.fr.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mottet
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage*; D017430:Prostate-Specific Antigen / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011788:Quality of Life
chemical_list: D000726:Androgen Antagonists; D009842:Oligopeptides; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D017430:Prostate-Specific Antigen